NEW YORK, June 25 /PRNewswire-FirstCall/ -- Dr. Joshua Schein, Chief Executive Officer of Lev Pharmaceuticals, Inc. ("Lev" or the "Company") (BULLETIN BOARD: LEVP.OB) , will present at the Jefferies Annual Healthcare Conference in New York City, NY on Wednesday, June 27, 2007.
The Lev Pharmaceuticals, Inc. presentation is scheduled to begin at 3:40 PM EDT. It will be accessible via webcast by clicking on the link: http://www.wsw.com/webcast/jeff18/levp.ob/.
The above link can be used for both the live and archived webcast. The webcast will automatically be archived on the date of the live event and will be available for 90 days.
For information about the Jefferies Annual Healthcare Conference, please visit: http://www.jefferies.com/.
ABOUT LEV PHARMACEUTICALS
Lev is a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases. The Company's lead product candidate is C1-inhibitor (C1-INH), which it is developing for the acute and prophylactic treatment of hereditary angioedema (HAE), a rare and life-threatening genetic disease. The Company recently announced positive results from the acute portion of its registrational Phase III clinical trial for HAE, designated CHANGE (C1- inhibitor in Hereditary Angioedema Nanofiltration Generation evaluating Efficacy). In addition, Lev has recently completed the prophylactic portion of the CHANGE trial. Based on the results of the acute study, the Company intends to submit a Biologics License Application (BLA) to the Food and Drug Administration in July 2007. Additionally, the Company intends to submit the data from the prophylactic study, if positive and supportive, as an amendment to the BLA. The Company is also evaluating the development of C1-INH for the treatment of acute myocardial infarction, or heart attack, and selective other diseases and disorders in which inflammation is known or believed to play an underlying role. Lev's C1-INH has been granted orphan drug status for the treatment and prevention of HAE attacks, potentially securing, upon approval, market exclusivity for seven years. The Company has also received fast track designation status from the FDA, which facilitates the development and expedites the review of drugs and biologics intended to treat serious or life- threatening conditions and that demonstrate the potential to address unmet medical needs.
For more information about Lev and C1-INH for the treatment of HAE, please contact the Company directly at 212-682-3096 or visit the Company's website at http://www.levpharma.com/.
Legal notice to investors: Certain matters discussed in this news release are "forward-looking statements." These forward-looking statements, which apply only on the date of this release, generally can be identified by the use of forward-looking terminology such as "may," "will," "expects," "intends," "estimates," "anticipates," "believes," "continues" or words of similar import. Similarly, statements that describe Lev's future plans, objectives or goals are also forward-looking statements, which generally involve known and unknown risks, uncertainties and other facts that may cause the actual results, performance or achievements of Lev to be materially different from those expressed or implied by such forward-looking statements. Such factors may include the following: uncertainties associated with product development, the risk that Lev will not obtain approval to market its products, the risk that Lev's products will not gain market acceptance, the risks associated with dependence upon key personnel, the need for additional financing and other risks described in Lev's periodic reports filed with the Securities and Exchange Commission. These statements are based on our current beliefs and expectations as to such future outcomes and Lev disclaims any obligation to update the forward-looking statements made herein.
